Drug intelligence / Profile preview

CLBS23

Development stage: Preclinical
Lead developer: Lisata Therapeutics
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies

Overview

CLBS23 is an investigational cell therapy developed using proprietary tumor cell/dendritic cell technology. Originally developed by Caladrius Biosciences, it was out-licensed to AiVita Biomedical in May 2016 for worldwide use in the treatment of ovarian cancer. This candidate represents a strategy to leverage the body's immune system against cancer cells.

Beyond the preview

Go deeper on CLBS23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLBS23.

Explore the full profile